Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

IMMUNOGEN, INC. (IMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,569,211759,5
EBITDA-68,4-66,9-54,4-114-36,1-100
Operating profit (EBIT)-73,0-71,5-59,9-113-54,8-122
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-131-95,8-142
P/E ratio-19,1-14,3-20,3-4,40-6,71-5,90
EPS ( $ )-0,87-0,83-0,71-1,52-1,00-1,14
Dividend per Share ( $ )------
Yield------
Reference price ( $ )16.5911.8514.386.76.76.7
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt---19,2--
Finance195142278---
Operating income (EBITDA)-68,4-66,9-54,4-114-36,1-100
Leverage
(Debt/EBITDA)
----0,17x--
Capital Expenditure3,778,187,4314,04,936,30
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $-0,85 $-0,35 $-0,54 $
Cash Flow per Share-0,72 $-0,63 $-0,64 $-1,32 $0,02 $-0,97 $
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2017 Thomson Reuters
Financial Ratios

Size 2016e 2017e
Capitalization 1 037 M$ -
Entreprise Value (EV) 1 056 M$ 1 037 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS)
Capitalization / Revenue 15,0x 8,88x
EV / Revenue 15,3x 8,88x
EV / EBITDA -9,25x -28,7x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -7,88x -19,1x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -163% -46,9%
operating Leverage (Delta EBIT / Delta Sales) -4,63x 0,75x
Net Margin (Net Profit / Revenue) -190% -82,0%
ROA (Net Profit / Asset) -53,0% -31,8%
ROE (Net Profit / Equities) 2 183% -
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / CA   20,2% 4,22%
Cash Flow / Sales -295% 2,65%
Capital Intensity (Assets / Sales) 3,58x 2,58x
Financial Leverage (Net Debt / EBITDA) -0,17x -
EPS & Dividend